Not quite sure. Profitability still a ways off, but DES market is starting to turn around. As of 9/30 about a $120MM run rate with $90MM in cash. Taking a look at the short percentage, but I would think at $8 it becomes an easy double again as long as there is no increasing pushback from physicians on the price + intravascular use in the interventional setting.
Crap company - no earnings. Crap market. Management seems to have no clue about how to control costs and generate positive earnings. Barring a takeover or something like that this stock likely isn't going anywhere.